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Abstract
Background/aims—In the pre-HAART
era, HIV positive patients with CD4+ cell
counts below 50 cells ×106/l, and those with
detectable cytomegalovirus (CMV) DNA
in their peripheral blood, were considered
to be at high risk for the development of
CMV disease. With the start of highly
active antiretroviral therapy (HAART), a
restoration of immune function occurred
in these patients, and as a consequence
patients became less vulnerable to CMV
disease. Since it is not exactly known how
HAART influences CMV viral load in
peripheral blood and the incidence of
CMV disease in high risk HIV positive
patients a group of patients was followed
before and after initiation of HAART.
Methods—29 HIV positive patients, seen
in the first 3 months of 1996 at the AIDS
clinic of the Academic Medical Centre, at
high risk for development of CMV disease
(positive CMV DNA assay in blood and/or
CD4+ cell count below 50 cells ×106/l), not
receiving anti-CMVmaintenance therapy,
were included in a prospective cohort
study. HAART was started in the second
trimester of 1996. Patients were evaluated
for the occurrence of CMV retinitis, or
CMV disease elsewhere, comparing the
incidence of CMV events before and after
the start of HAART. Following the intro-
duction of HAART, CD4+ cell counts and
quantitative polymerase chain reaction
(PCR) for CMV DNA in blood were moni-
tored in all patients who remained alive
and were not receiving anti-CMV mainte-
nance therapy (n=22). Follow up was per-
formed until August 1998; the mean follow
up after the start of HAART was 14.9
months (range 8–22 months).
Results—In the pre-HAART period four
patients developed CMV disease, and four
died (without clinically manifest CMV
disease). After the start of HAART no
patient developed CMV disease or died.
With HAART, the mean CD4+ cell counts
increased from 34 cells ×106/l to 194 cells
×106/l at the end of follow up. CMV DNA
could be detected in the blood of 11
patients. Quantification showed a decline
in the amount of detectable DNA during
follow up. At the last examination only one
patient showed a positive PCR assay. This
was the only patient with a CD4+ cell
count remaining below 100 cells ×106/l.
Conclusion—In HIV positive patients at
high risk of CMV retinitis, either with a
positive CMV PCR assay in blood and/or
with CD4+ cell counts below 50 cell ×106/l,
HAART causes a dramatic decrease in the
occurrence of CMV disease. This decrease
is paralleled by an increase in CD4+ cell
count, and a decrease in the amount of
CMV DNA in the blood, which was below
detection levels in all patients with CD4+
cell counts above 100 cells ×106/l.
(Br J Ophthalmol 1999;83:1186–1189)
The presence of cytomegalovirus (CMV)
DNA either in whole blood or in cell free sam-
ples has been recognised as an important risk
factor, in addition to low CD4+ cell counts, for
the development of clinical manifest CMV dis-
ease in HIV positive patients. Studies on serum
or plasma samples reported useful statistical
variables for CMV DNA polymerase chain
reaction (PCR) assays in predicting CMV dis-
ease (sensitivity between 75% and 90%;
specificity between 60% and 85%; positive
predictive value between 60 and 70%; negative
predictive value between 80 and 98%).1–6 The
overall incidence of CMV retinitis in these
studies during a follow up period of 12 months
was between 25% and 35%. Spector et al
reported a 12 month Kaplan–Meier CMV dis-
ease event rate of 14% in PCR CMV negative
patients and of 43% in the PCR positive
patients, corresponding to a 3.4-fold increased
risk of developing CMV disease. In over 90%
of cases CMV disease manifested itself as
retinitis.2
The use of antiretroviral combination
therapy—for example, triple threrapy consist-
ing of two reverse transcriptase inhibitors and
one protease inhibitor, often called highly
active antiretroviral therapy (HAART), has
resulted in a dramatic change in the morbidity
associated with HIV. A significant decline in
the incidence of CMV disease has been
reported in patients receiving this combination
antiretroviral therapy.7 8 Van den Horn et al
reported that patients with CMV retinitis
treated with HAART showed no recurrences
during a follow up period of 42–52 weeks pro-
vided the CD4+ cell counts remained above
100 cells ×106/l.9 HAART induces a rapid
redistribution and eventually a restoration of
the immune system, and as a result, patients,
normally expected to be at high risk for devel-
oping CMV retinitis or recurrences of already
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present CMV retinitis, are again able to
suppress active CMV infection.
Since it is not known exactly how HAART
influences CMV viral load in peripheral blood
or the incidence of CMV disease in high risk
HIV positive patients, we assessed a group of
patients before and after the start of HAART.
Patients and methods
PATIENT SELECTION
Patients were selected from a group of 100
consecutive HIV positive patients seen in
March and April 1996 at the AIDS clinic of the
Academic Medical Center of the University of
Amsterdam. Eligible patients either tested
positive for CMV PCR in blood (n=18), or had
a CD4+ count below 50 cells ×106/l (n=15).
With two exceptions all PCR positive patients
had a CD4+ count below 50 cells ×106/l . Four
patients refused to participate. All other
patients (n=29) underwent a full ophthalmo-
logical examination, including funduscopy in
mydriasis at baseline.
A CMV event could be either a CMV retini-
tis, defined as a necrotising retinitis with char-
acteristic “cheese-like” appearance with or
without haemorrhages, as observed by an
experienced ophthalmologist, or extraocular
CMV disease, for which diagnosis immunohis-
tological proof had to be present.
Before the start of HAART four patients died
without clinically manifest CMV disease, after
4, 7, 9, and 15 weeks respectively. The mean fol-
low up period for the other patients from the
start of the study to the start of HAART was 5
months (range 4–6 months). All patients were
given HAART in the second trimester of 1996.
HAART consisted of triple therapy, using a
combination of two reverse transcriptase inhibi-
tors and one protease inhibitor.
Three patients developed CMV retinitis and
received anti-CMV maintenance therapy.
These patients were excluded from further fol-
low up. Mean follow up after the start of
HAART for those patients not receiving
anti-CMV maintenance therapy (n= 22), was
14.9 months (range 8–22 months).
Between November 1996 and July 1998 the
22 patients without anti-CMV maintenance
therapy underwent a full ophthalmological
examination, including funduscopy in mydria-
sis, every month during the first 6 months, and
every other month during the remaining part
of follow up. At the same time blood samples
were taken for quantitative PCR analysis. At
each visit patients were asked for complaints
related to oesophagitis, colitis, pneumonia, or
neuropathy. Additionally at each visit, the
treating physician from the department of
internal medicine received a questionnaire and
was explicitly asked for any signs of extraocular
CMV disease. CD4+ cell counts were per-
formed every third month.
PCR ANALYSIS
CMV DNA was purified from 50 µl EDTA
blood specimens together with 70 molecules of
internal control (IC) DNA as described previ-
ously, using 20 µl of size fractionated silica
particles.10 DNA was eluted in 100 µl TE buVer
(10 mM TRIS, 1 mM EDTA, pH 8.0). CMV
DNA levels in blood were determined as
described previously (Boom R, Sol C, Weel J, et
al. A highly sensitive assay for detection and
quantification of human cytomegalovirus DNA
in serum and plasma by PCR and electro-
chemiluminescence, submitted). In short, puri-
fied DNA (25 µl) was subjected to a 35 cycle
PCR with a single primer pair which amplifies a
578 bp DNA fragment from exon 4 of the major
immediate early gene of CMV and a fragment of
identical size and GC content from IC DNA.
The amounts of CMV and IC PCR products
were subsequently determined by electro-
chemiluminescence (ECL) in the QPCR Sys-
tem 5000 (Perkin Elmer) after hybridisation
with (TRIS (2,2'-bipyridine) ruthenium (II)
chelate) (TBR) labelled probes specific for
either CMV or IC amplimers. The viral load
(expressed as copies CMV/ml blood) was calcu-
lated from the ratio (R) of CMV over IC ECL
signals (after background correction) by the
algorithm “copies CMV/ml blood = R × 1400”.
STATISTICAL ANALYSIS
For statistical analysis we compared the CMV
event rate, during follow up before the start of
HAART, with CMV event rate following the
start of HAART, using the Kaplan–Meier
method and the log rank test.11
Results
Four patients, all belonging to the CMV PCR
positive patient group, developed a clinically
manifest CMV disease in the pre-HAART
period, after 1, 7, 9, and 12 weeks. Three
patients were diagnosed with a CMV retinitis
and all were put on maintenance therapy after
successful induction therapy. One patient
developed a CMV colitis and only received a 3
week induction therapy. Additionally, four
patients died before the start of HAART, with-
out clinically manifest CMV disease, after 4, 7,
8, and 17 weeks respectively (Table 1).
Table 1 EVect of HAART on occurrence of CMV events and survival in HIV positive patients at high risk for developing
CMV disease
Before HAART (n=29)
Time to event or
death (months)*
After HAART (n=22)
PCR+
(n=16)
PCR−
(n=13)
PCR+
(n=10)
PCR−
(n=12)
CMV events (n) 4 — 0.5, 2, 2, 3 — —
Death (n) 3 1 1, 2, 2, 4 — —
Living, without anti-CMV maintenance therapy (n) 10 12 — 7 11
Mean follow up (months) 5.0† 14.9‡
HAART = highly active antiretroviral therapy; PCR = polymerase chain reaction; + = positive result, − = negative result; *time
between start of study and occurrence of event/death; †mean follow up between start of study and start of HAART; ‡mean follow
up following start of HAART.
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Following the start of HAART none of the
22 patients not receiving anti-CMV mainte-
nance treatment developed clinically manifest
CMV disease during a mean follow up of 14.9
months (range 8–22 months), and none of
these patients died.
Statistical analysis comparing the incidence
of CMV disease in patients before and after the
start of HAART using the Kaplan–Meier
method and the log rank test resulted in a p
value of 0.05.
Most patients responded to HAART with a
steady increase in their CD4+ cell counts
(Table 2). The mean CD4 positive count
increased from 32 cells ×106/l (range 10–150)
at the start of follow up, through 144 cells
×106/l (range 40 to 260) halfway, to 194 cells
×106/l (range 60–500) at the last examination.
With the exception of one patient (patient
number 13), all CD4+ cell counts were over
100 cells ×106/l at the last examination.
In eight patients a positive CMV PCR test
was obtained during follow up after the start of
HAART (Table 2). Quantification of the PCR
test showed a decrease of the amount of CMV
DNA detectable in the peripheral blood of all
these patients. At the seventh examination,
longest follow up 10 months after the start of
HAART, none of the tested patients had
detectable CMV DNA in their blood. How-
ever, in patient 7, 12 months following start of
HAART, 280 CMV copies/ml could be
measured, and in patient 14, 14 months
following the start of HAART, 98 CMV
copies/ml could be detected (not shown in
Table 2). At the last examination, after a mean
follow up of 14.9 months, only one patient
(number 13) tested positive, with a CMV viral
load of 727 copies/ml. This was also the only
patient with a CD4+ cell count less than 100
cells ×106/l.
Discussion
In this study we present data showing that in
22 patients, previously considered to be at
extremely high risk for developing CMV
disease, not one new case of CMV disease
manifested itself during a mean follow up of
14.9 months (range 8–22 months).
HAART resulted in a gradual rise in CD4+
lymphocyte counts and a gradual drop in
CMV viral load in the peripheral blood. At the
last examination CMV DNA became undetec-
table, with the exception of one patient whose
CD4+ cell count remained less than 100 cells
×106/l. No patient died during follow up.
Comparing the incidence of CMV disease in
the patients before and after the start of
HAART, using the Kaplan–Meier method with
the log rank test, we found a statistically
significant, albeit weak, diVerence between
both observation periods (p =0.05). A placebo
controlled trial (withholding HAART to these
patients) was considered to be unethical.
Patients with a history of extraocular CMV
disease have been reported to be especially
prone to the subsequent development of CMV
retinitis. Over 85% of these patients developed
a CMV retinitis after a mean follow up of 6.4
months.12 Not one of the three patients (patient
nos 9, 10, and 22, Table 2) in this study with
gastrointestinal CMV disease developed CMV
retinitis during follow up after the start of
HAART.
The fact that no clinically manifest CMV
disease occurred in our group of HIV positive
patients can only be explained by the success of
the HAART treatment. Others have also
reported the decreased incidence of CMV dis-
ease in HIV positive patients with favourable
responses to HAART treatment.7–9 The de-
crease of CMV viral load found in this study
confirms the restoration of the immune system,
Table 2 EVect of HAART on CD4+ cell counts and CMV viral load in 22 HIV positive patients, without anti-CMV maintenance therapy, at high risk
for developing CMV disease
Patient
No
Before HAART After HAART Last exam
Exam 0 Exam 1 Exam 2 Exam 3 Exam 4 Exam 5 Exam 6 Exam 7
After n
months PCR CD4+CD4+ PCR CD4+ PCR PCR PCR CD4+ PCR PCR PCR CD4+ PCR
1 10 1469 70 — — — 110 — — — 230 — 18 — 130
2 150 914 150 — — — 140 — — — 180 — 18 — 150
3 20 1136 210 — — — 250 — — — 250 — 12 — 170
4 20 562 90 — — — 220 — — — ND — 9 — 460
5 40 1529 160 — — — 130 — — 171 140 — 18 — 170
6 40 382 30 2071 1474 ND ND ND ND ND 100 — 12 — 100
7 40 2355 100 — — 376 150 584 — — 170 — 16# — 180
8 90 1259 170 384 — — 200 — — — 190 — 22 — 200
9* 30 1423 90 — — 947 100 — ND ND ND ND 13 — 100
10* 20 604 140 133 — — 200 — — — 200 — 16 — 200
11 30 — 10 — — 237 ND ND — — ND ND 12 — 180
12 20 — 60 6488 1464 — 130 534 602 — 140 — 13 — 120
13 20 — 30 — 186 875 40 — 346 — 20 — 16 727 60
14 10 — 110 — — — 260 — — — 170 — 16* — 340
15 20 — 60 — — — 90 — — — 80 — 17 — 250
16 50 — 190 — ND ND 130 — ND ND ND ND 9 — 130
17 30 — 70 — — — 150 — — — 170 — 16 — 110
18 10 — 230 — — — 60 — — — 170 — 18 — 250
19 10 — 80 — — ND 100 — — — 130 — 13 — 190
20 30 — 140 — — ND ND ND ND ND ND 8 — 140
21 30 — 50 — — — 80 — — — ND — 14 — 130
22* 30 — 120 — — — 190 — 148 — 400 — 22 — 500
CD4+ = CD4+ cell count (cells ×106/l); HAART = highly active antiretroviral therapy; PCR = quantitative polymerase chain reaction, in copies CMV ×106/ml; − =
negative result; ND = not done; exam 0 = first examination, at intake, before the start of HAART; exam 1–7 = examinations, monthly, after the start of HAART. After
the 7th examination, follow up scheduled every other month, results not shown. *Patient 9, 10, and 22 previous diagnosis of extraocular CMV disease.;†patient 7 one
positive test 12 months after start HAART (280 copies/ml); ‡patient 14 one positive test 14 months after start HAART (98 copies/ml); last exam after n months =
last examination of the patient at n months after the start of HAART.
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enabling the patients to successfully suppress
reactivation from their latent CMV infection.
All four patients with clinically manifest
CMV disease in the pre-HAART period
belonged to the group of patients with a CMV
PCR positive blood test. This observation con-
firms the predictive value of the PCR assay,
even though the patient number is small, and
pre-HAART follow up short (sensitivity 100%,
specificity 55%, positive predictive value 23%,
negative predictive value 100%). The test
results compare favourably with those reported
in the literature, suggesting at least an equal
sensitivity.1–6
Although HAART is considered very eVec-
tive in treating HIV infection, with a sometimes
dramatic improvement in the clinical manifes-
tations of opportunistic infections, CMV dis-
ease has been reported in HIV positive patients
after the start of HAART, even after a rise of
CD4+ lymphocyte count above 100 cells
×106/l.13 14 Diagnosis was made very shortly
after the initiation of HAART, within a 4–8
week period. During the rest of follow up after
these first 2 months, not one new case of CMV
disease occurred in these studies.
After the start of HAART, uveitis or vitritis
has been described in some patients with CMV
retinitis.13 This was believed to be due to resto-
ration of the previously deficient immune
response in these patients, leading to an
intraocular inflammatory response against the
virus. In our study no new case of CMV retini-
tis developed after the start of HAART, nor did
any patient showed signs of uveitis.
We conclude that in HIV positive patients at
high risk for development of CMV disease,
either with a positive CMV PCR assay in blood
and/or with CD4+ lymphocyte counts below
50 cells ×106/l, HAART causes a dramatic
decrease in the occurrence of CMV disease.
This decrease is paralleled by an increase in
CD4+ lymphocyte count, and a decrease in the
amount of CMV DNA in the blood, which
becomes undetectable in all patients with
CD4+ cell counts above 100 cells ×106/l.
1 Rasmussen L, Zipeto D,Wolitz RA, et al. Risk for retinitis in
patients with AIDS can be assessed by quantification of
threshold levels of cytomegalovirus DNA burden in blood.
J Infect Dis 1997;176:1146–55.
2 Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovirus
(CMV) DNA load predicts disease and survival in AIDS
patients. J Clin Invest 1998;101:497–502.
3 Dodt KK, Jacobson PH, Hofmann B, et al. Development of
cytomegalovirus (CMV) disease may be predicted in HIV-
infected patients by CMV polymerase chain reaction and
the antigenemia test. AIDS 1997;11:F21–8.
4 Shinkay M, Bozette SA, Powderly W, et al. Utility of urine
and leukocyte cultures and plasma DNA polymerase chain
reaction for identification of AIDS patients at risk for
developing human cytomegalovirus disease. J Infect Dis
1997;175:302–8.
5 Laue T, Mertenskotter T, Grewing T, et al. Clinical signifi-
cance of qualitative human Cytomegalovirus (HCMV)
detection in cell-free serum samples in HIV-infected
patients at risk for HCMV disease. AIDS 1997;11:1195–6.
6 Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus
(CMV) viraemia detected by polymerase chain reaction
identifies a group of HIV-positive patients at high risk of
CMV disease. AIDS 1997;11:889–93.
7 Ash S. Combination HIV therapy and opportunistic
infections of the eye in people with AIDS. Br J Ophthalmol
1998;82:981–3.
8 Walsh JC, Jones CD, Barnes EA, et al. Increasing survival in
AIDS patients with cytomegalovirus retinitis treated with
combination antiretroviral therapy including protease
inhibitors. AIDS 1998;12:613–8.
9 Van den Horn GJ, Meenken C, Danner SA, et al. EVects of
protease inhibitors on the course of CMV retinitis in rela-
tion to CD4+ lymphocyte responses in HIV+ patients.Br J
Ophthalmol 1998;82:988–90.
10 Boom R, Sol CJ, Salimans MM, et al. Rapid and simple
method for purification of nucleic acids. J Clin Microbiol
1990;28:495–503.
11 Altman DG. Comparing groups—categorical data. Practical
statistics for medical research. 1st ed. London: Chapman &
Hall, 1991:229–72.
12 Verbraak FD, van den Horn GJ, van der Meer JTM, et al.
Risk of developing CMV retinitis following non-ocular
CMV disease in AIDS patients. Br J Ophthalmol 1998;82:
748–50.
13 Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus
retinitis after initiation of highly active antiretroviral
therapy. Lancet 1997;349:1443–5.
14 Mallolas J, Arrizabalaga J, Lonca M, et al. Cytomegalovirus
disease in HIV-1-infected patients treated with protease
inhibitors. AIDS 1997;11:1785–7.
Influence of HAART on the development of CMV disease in HIV positive patients 1189
 group.bmj.com on December 27, 2011 - Published by bjo.bmj.comDownloaded from 
doi: 10.1136/bjo.83.10.1186
 1999 83: 1186-1189Br J Ophthalmol
 
Frank D Verbraak, René Boom, Pauline M E Wertheim-van Dillen, et al.
 
positive patients at high risk for CMV disease
on the development of CMV disease in HIV 
Influence of highly active antiretroviral therapy
 http://bjo.bmj.com/content/83/10/1186.full.html
Updated information and services can be found at: 
These include:
References
 http://bjo.bmj.com/content/83/10/1186.full.html#related-urls
Article cited in: 
 
 http://bjo.bmj.com/content/83/10/1186.full.html#ref-list-1
This article cites 13 articles, 6 of which can be accessed free at:
service
Email alerting
box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic
 (751 articles)Epidemiology   
 (535 articles)Eye (globe)   
 (1198 articles)Retina   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on December 27, 2011 - Published by bjo.bmj.comDownloaded from 
